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Vascular endothelial dysfunction after anthracyc­
lines treatment in children with acute lymphoblastic 
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Purpose: Anthracyclines have been utilized in the treatment of children with acute lymphoblastic 
leukemia (ALL). Recent studies have shown that anthracyclines may induce toxicity in the vascular 
endothelium. This study was performed using brachial artery reactivity (BAR) to evaluate vascular endo  thelial 
function in ALL patients who were treated with anthracycline chemotherapy. 
Methods: We included 21 children with ALL who received anthracycline chemotherapy and 20 healthy 
children. The cumulative dose of anthracyclines in the ALL patients was 142.5±18.2/m
2. The last anth­
racycline dose was administered to the patients 2 to 85 months prior to their examination using BAR. 
The diameter of the brachial artery was measured in both groups using echocardiography, and BAR 
was calculated as the percentage change in the arterial diameter after release of the cuff relative to the 
baseline vessel diameter. 
Results: In the anthracycline­treated group, BAR was observed to be 3.4%±3.9%, which was significantly 
lower than that observed in the control group (12.1%±8.0%, P<0.05). The time elapsed after the last 
anthracycline treatment and the age at the time of treatment did not affect the change in BAR (P=0.06 
and P=0.13, respectively). 
Conclusion: These results provided evidence that treatment of ALL patients with anthracycline results 
in endothelial dysfunction. A larger cohort study and a longer follow­up period will be required to clarify 
the relationship between endothelial dysfunction resulting from anthracycline treatment for childhood 
ALL and occurrence of cardiovascular diseases later in life. 
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Introduction
The development of new supportive agents and antibiotics has facilitated the use of 
more intensified and effective anticancer drugs which enhance the long term survival of 
childhood acute lymphoblastic leukemia (ALL) patients
1). With the increased sur  vival rate 
of children with ALL, attention has now shifted toward the long-term comp  lications of 
this intensified treatment
2).
Lately the scientific interest in evaluating the impact of vascular endothelial dysfunc  tion in 
ALL is increasing. ALL itself, chemotherapeutic agents, or other conditions (e.g., sepsis) 
can result in the vascular endothelial dysfunction
3). Among chemotherapeutic agents 
anthracyclines in particular have been shown to have potential to cause vascular endothelial 
dysfunction
4,5). 
The vascular endothelium is an active, dynamic tissue which controls many important 
functions including secretion of factors regulating vascular tone, platelet aggregation and 131 http://dx.doi.org/10.3345/kjp.2013.56.3.130
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leuko  cyte interactions. Endothelial dysfunction is an important 
factor in the development of atherosclerosis, hypertension, 
coronary artery disease and heart failure
6). In this regard, an-
thracyclines could be a causative agent related to the pathoge-
nesis of atherosclerosis or other cardiovascular diseases.
Vascular endothelial function can be characterized by flow- 
mediated vasodilatation of the brachial artery, which is mea-
sured by comparing the brachial artery diameter at rest to the 
diameter after increased forearm blood flow. Over the past de-
cade, noninvasive technique, brachial artery reactivity (BAR), has 
been developed in order to evaluate vascular endo  thelial function
7). 
Although there are some technical and interpretive limitations, 
BAR has been widely used to evaluate the vascular endothelial 
function in patients with cardiovascular diseases including 
artherosclerosis, diabetes mellitus, hypercholestero  lemia, coronary 
artery disease and peripheral vascular disease
8.9).
In this study, we used BAR in order to evaluate the function 
of the vascular endothelium in patients to whom had been ad-
ministered chemotherapy with anthracyclines for the treatment of 
childhood ALL.
Materials and Methods
1. Patients 
An informed consent was obtained from the guardians of all 
enrolled participants and the study protocol was approved by the 
Gachon Medical School Ethics Committee in October, 2010. Twenty-
one ethnic Korean children, including 11 boys and 10 girls aged 
4 years to 18 years with a median age of 11 years, who had been 
newly diagnosed with high risk ALL were enrolled onto this study 
and administered anthracyclines at the Pedia  trics Department of 
Gil Hospital, Gachon University in Incheon, Korea. The enrolled 
patients were treated with a dosing regimen consisting of induction, 
consolidation with cranial irradiation, interim maintenance, a single 
delayed intensification and a maintenance phase. Daunomycin 
was administered in the induction phase and doxorubicin was 
administered in the delayed intensification phase. As a consequence, 
the cumulative dose of anthracyclines was 142.5±18.2/m
2 prior to 
the maintenance phase. The other chemotherapeutic agents given 
to the patients included vincristine, prednisolone, L-asparaginase, 
cyclophosphamide, 6-mercaptopurine, methotrexate, intrathecal 
cytosine arabinoside and methotrexate. We excluded the 
participation of two patients who had existing conditions known 
to influence BAR results including hypertension, hyperlipidemia, 
diabetes mellitus, smoke exposure, cardiovascular surgery or 
peripheral vascular disease. We performed the BAR test with enrolled 
subjects who had com  pleted their scheduled therapy or were in the 
maintenance phase after the delayed intensification treatment. A 
control group of 20 ethnic Korean children composed of 9 boys and 
11 girls, aged 2 years to 16 years with a median age of 9 years, were 
enrolled in this study. In addition, we selected a control group who 
were healthy and without any major medical illness or conditions 
known to influence BAR results. 
The demographic characteristics of both the control and 
treatment groups are shown in Table 1. The differences in age 
and gender between the groups were found to be negligible. In 
addition, physical characteristic differences including height 
and body weight between the groups were also found to be 
negligible.
2. Assessment of vascular endothelial reactivity 
All investigations were carried out using a 5/12-MHz linear 
array ultrasound device (ATL 3000, Philips Healthcare, Bothell, 
WA, USA). A single experienced pediatric cardiologist (DYC), 
blinded to the subject’s status, measured the vessel diameter. 
Each subject remained in a supine position on the examination 
table for at least 5 minutes prior to testing. The baseline blood 
pressure was obtained using a manual blood pressure cuff. 
Electrocardiographic leads were connected to the patient and the 
signal was displayed on a monitor. The baseline images of the 
brachial artery were obtained approximately 5 cm proxi  mal to 
the antecubital crease. Hyperemia was induced by inflating the 
blood pressure cuff on the arm in order to occlude arterial flow 
(40 mmHg above the measured resting systolic blood pressure) 
for 5 minutes, and then rapidly deflating the cuff. The reactive 
hyperemia images were obtained 1 minute after cuff deflation. 
The diameter of the brachial artery was measured from anterior 
to posterior and between the media and adventitia (m-line) at the 
end diastolic. The arterial mean diameter was averaged from the 
images obtained during the three cardiac cycles synchronized 
with the R-wave peaks on the electrocardiogram. BAR was 
calculated as the percentage change of arterial diameter after 
release of the cuff relative to the baseline vessel diameter. 
Table 1. Demographic and clinical characteristics of anthracycline-
treated and control groups
Characteristic Anthracyclines
treated group Control group P value
Age (yr) 10.3±4.3 9.6±4.1 0.42
Male : Female 11:10 9:11 1.00
Height (cm) 140.0±22.0 135.0±22.8 0.47
Weight (kg)   43.5±22.0   33.3±13.8 0.47
Systolic BP (mmHg) 111.1±15.6 108.4±10.9 0.59
Occlusive BP (mmHg) 150.4±14.1 148.9±10.7 1.00
Values are presented as mean±standard deviation.
BP, blood pressure.http://dx.doi.org/10.3345/kjp.2013.56.3.130
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3. Statistical analysis
Results were expressed as mean±standard deviation. Compari-
sons between the two groups were performed using an indepen-
dent samples t-test, Mann-Whitney test and chi-square test. The 
variables were evaluated by Spearman’s rank correlation. For 
all analyses, P<0.05 was accepted as statistically significant. All 
statistical analyses were performed using MedCalc ver. 12.3.00 
(MedCalc, Mariakerke, Belgium).
Results
1. Comparison of BAR results between the treatment and 
control groups 
Occlusive pressure was 150.4±14.1 mmHg in the anthracyc-
lines treated group and 148.9±10.7 mmHg in the control group 
(P=1.0). Resting vessel diameter was 3.3±0.6 mm in the anthra-
cyclines treated group and 3.1±0.4 mm in the control group 
(P=0.36). In the anthracyclines treated group, the average BAR 
was 3.4%±3.9%. The control group had an average BAR of 
12.1%±8.0% (Table 2). The difference in BAR between these groups 
was statistically significant (P<0.05) (Fig. 1). 
2. BAR change according to the elapsed time in the treatment 
group
There was no correlation between the elapsed time after the 
last anthracyclines administration and BAR among the treat  ment 
group (r=0.42, P=0.06) (Fig. 2). 
3. BAR results relative to age at time of treatment
There was no correlation between the patient age at time of 
anthracyclines administration and BAR among the treatment 
group (r=0.34, P=0.13) (Fig. 3).
Discussion      
With advances in treatment, the survival rate of childhood 
leukemia cases has significantly improved. However, the increase 
in the childhood leukemia survival rate is accompanied by 
long term adverse effects impacting the quality of life for adult 
survivors
10). The survival rate of children diagnosed with ALL 
has been improved with the use of anthracyclines, yet their use 
is accompanied by high risk factors
1). The use of anthra  cyclines is 
known to be related to the development of irreversible cardio-
myopathy, and this development occurs more frequently in 
cases of high cumulative doses. In recent years, this potent anti-
neoplastic drug has been reported to produce toxicity af  fecting 
the vascular endothelium
4,5). Vascular endothelial cells, lining 
Table 2. Comparison of baseline vessel diameter and brachial artery 
reactivity in anthracycline-treated and control groups
Anthracyclines
treated group
Control
group P value
Baseline vessel diameter (mm) 3.3±0.6 3.1±0.4   0.36
Brachial artery reactivity (%) 3.4±3.9 12.1±8.0 <0.05
Values are presented as mean±standard deviation.
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Fig. 1. Brachial artery reactivity was higher in the control group than in the 
anthracycline­treated group (P<0.05). The vertical bar represents the values 
from the lower to upper quartile (25th to 75th percentile). The middle line 
represents the mean. The line extending between the minimum and maximum 
values includes the outside and far out values. The circles represent each 
value. BAR, brachial artery reactivity.
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Fig. 2. The correlation between elapsed time after the final anthracycline 
treatment and brachial artery reactivity (BAR) was not statistically significant 
(r=0.42, P=0.06). 133 http://dx.doi.org/10.3345/kjp.2013.56.3.130
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the entire circulatory system, have distinct and unique functions 
affecting maintenance of blood circulation and flui  dity as well 
as regulation of vascular tone, coagulation, and inflammatory 
responses. Therefore an alteration of regulatory function of vas-
cular endothelium by damage is related to the development of 
cardiovascular disease, including athero  sclerosis and hypertension
11). 
Damage of the vascular endothelium caused by diverse insults 
such as antiendothelial antibodies, disturbed cytokines, viral 
infections, free radical formation or oxidation of lipids, has been 
implicated in cardiovascular diseases, in  cluding atherosclerosis 
and hypertension
11).
Recent research has revealed that anthracyclines induce vascular 
endothelial damage by a multifactorial process
12). The main 
mechanism leading to damage is the inhibition of endo  thelial 
nitric oxide synthase (eNOS) due to the action of anth  racyclines 
binding to the reductase domain of eNOS
13). As a consequence, 
there is not only a reduction in nitric oxide (NO) production but 
also an increase in superoxide generation. Decreased availability 
of NO, which is the main vasodilator and the regulator of other 
protective properties of the endo  thelium, diminishes vascular 
reactivity. In addition, the increase in free radicals may play a role 
in the apoptosis of vas  cular endothelial cells
14,15). These events 
could be related to the development of cardiovascular diseases 
including atheroscle  rosis and hypertension, and lead to heart 
failure. 
Evaluation of BAR, an endothelium-dependent function, 
has been used to evaluate vascular endothelial function
7,8). In 
practice, a measure of BAR in breast cancer patients undergoing 
chemotherapy with adriamycin (60 mg/m
2) revealed a signifi-
cant reduction in flow-mediated dilation from 6.5%±1% (before 
administration) to 2.5%±1% (just after administration)
4). In ad  dition, 
serum nitrite and nitrate concentrations fell after adriamycin 
administration, indicating insufficient NO synthesis. Another 
recent study, examining childhood cancer patients treated with 
a cumulative dose of more than 300 mg/m
2 of anthracyclines 
demonstrated that the BAR for these patients significantly 
decreased as compared to a healthy control group as 3.8%±3.4% 
and 6.7%±3.3%, respectively
5). Our study of childhood ALL 
patients treated with anthracyclines also showed similar results 
whereby BAR was 3.4%±3.9% in the treatment group and 
12.1%±8.0% in the control group. In two previous human studies, 
the anthracyclines doses administered were 60 mg/m
2 to over 300 
mg/m
2, how ever, both of those studies showed that patient BAR 
results diminished. The administered dose of anthracyclines in 
our study was around 140 mg/m
2 and also resulted in diminished 
BAR results. These results suggested that the anthracyclines dose 
does not affect BAR results, although evaluation of the toxicity 
of doxorubicin as it effects vascular endothelium using the organ 
culture method revealed that it induces apoptotic cell death 
followed by impairment of endo  thelium-dependent relaxation 
in a dose- and time-dependent manner
12). A larger cohort study 
is needed in order to evaluate the magnitude of dose which 
provokes injury to the vascular endothelium.
It is not clear yet that anthracyclines induce vascular endo  thelial 
damage by rapid-onset process or mechanism which needs time 
such as apoptosis. In our study BAR was not related to the elapsed 
time after the last anthracyclines was administered. The small 
numbers of patients enrolled in the study might affect the result of 
the relationship between final treatment time and BAR findings. 
Further studies in a larger group of patients and with a long term 
follow up period are required. 
It is unknown whether or not age is a significant factor in the 
vulnerability of vascular endothelium to the toxic effects of 
anthracyclines. In our study, the age at anthracyclines admini-
stered did not affect BAR results, indicating that the age factor 
was not important in the endothelial dysfunction induced by 
anthracyclines.
Although we investigated endothelial dysfunction in the 
brachial artery, which is a superficial artery, vasodilator changes in 
the brachial artery correlate well with coronary artery function
16). 
Our study results suggested that the endothelial dysfunction due to 
treatment may be related to and may play an important role in the 
progression of cardiovascular disease. In addition to endothelial 
dysfunction, survivors of childhood ALL suffer cardiovascular 
risk factors such as obesity, hyperli  pidemia, physical inactivity, 
insulin resistance and metabolic syndrome
17). From a clinical point 
of view, children treated with anthracyclines are at risk of early 
cardiovascular disease. Thus, cardiovascular disease risk factors 
such as hypertension, hyper  cholesterolemia, smoking, diabetes 
and obesity should be mo  nitored and controlled. 
In this human study, it was revealed that the around 140 
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Fig. 3. The correlation between patient age at anthracycline administration 
and brachial artery reactivity (BAR) was not statistically significant (r=0.34, 
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mg/ m
2 dose of anthracyclines induces the vascular endothelial 
dysfunction in ALL patients. A limitation of this study is that 
the other which may effect on vascular endothelium, such 
as other chemotherapeutic agents used in conjunction with 
anthracyclines and cranial radiation therapy and metabolic 
problems by ALL itself, were not considered. As the endothelial 
independent dilation was not evaluated, we could not determine 
whether a defect in the smooth muscle contributed to the de-
crease in BAR. The small number of patients enrolled in this 
study might affect the result of this study. Also, gender which 
might affect the BAR was not evaluable because the enrolled 
subjects were small.
Additional follow-up over many years would be necessary in 
order to confirm that endothelial dysfunction in anthracy  clines 
treated patients is associated with subsequent cardiovas  cular 
diseases. 
Conflict of interest
No potential conflict of interest relevant to this article was 
reported.
References
 1.   Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N 
Engl J Med 2006;354:166-78.
 2.   Bhatia S. Late effects among survivors of leukemia during child-
hood and adolescence. Blood Cells Mol Dis 2003;31:84-92.
 3.   Hatzipantelis ES, Athanassiou-Metaxa M, Gombakis N, Tzimouli 
V, Taparkou A, Sidi-Fragandrea V, et al. Thrombomodulin and von 
Willebrand factor: relation to endothelial dysfunction and disease 
outcome in children with acute lymphoblastic leukemia. Acta 
Haematol 2011;125:130-5.
 4.   Duquaine D, Hirsch GA, Chakrabarti A, Han Z, Kehrer C, Brook 
R, et al. Rapid-onset endothelial dysfunction with adriamycin: 
evidence for a dysfunctional nitric oxide synthase. Vasc Med 2003; 
8:101-7.
 5.   Chow AY, Chin C, Dahl G, Rosenthal DN. Anthracyclines cause 
endothelial injury in pediatric cancer patients: a pilot study. J Clin 
Oncol 2006;24:925-8.
 6.   Vita JA. Endothelial function. Circulation 2011;124:e906-12.
 7.   Corretti M. Brachial artery reactivity: clinical tool or research toy? J 
Am Soc Echocardiogr 2004;17:693-6.
 8.   Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau 
F, Creager MA, et al. Guidelines for the ultrasound assessment of 
endothelial-dependent flow-mediated vasodilation of the brachial 
artery: a report of the International Brachial Artery Reactivity Task 
Force. J Am Coll Cardiol 2002;39:257-65.
 9.   Lieberman EH, Gerhard MD, Uehata A, Selwyn AP, Ganz P, Yeung 
AC, et al. Flow-induced vasodilation of the human brachial artery 
is impaired in patients <40 years of age with coronary artery 
disease. Am J Cardiol 1996;78:1210-4.
  10.   Pui CH, Pei D, Sandlund JT, Campana D, Ribeiro RC, Razzouk 
BI, et al. Risk of adverse events after completion of therapy for 
childhood acute lymphoblastic leukemia. J Clin Oncol 2005;23: 
7936-41.
  11.   Ross R. The pathogenesis of atherosclerosis: a perspective for the 
1990s. Nature 1993;362:801-9.
  12.   Murata T, Yamawaki H, Yoshimoto R, Hori M, Sato K, Ozaki H, et 
al. Chronic effect of doxorubicin on vascular endothelium assessed 
by organ culture study. Life Sci 2001;69:2685-95.
  13.   Vásquez-Vivar J, Martasek P, Hogg N, Masters BS, Pritchard KA 
Jr, Kalyanaraman B. Endothelial nitric oxide synthase-dependent 
superoxide generation from adriamycin. Biochemistry 1997;36: 
11293-7.
  14.   Kalivendi SV, Kotamraju S, Zhao H, Joseph J, Kalyanaraman B. 
Doxorubicin-induced apoptosis is associated with increased 
transcription of endothelial nitric-oxide synthase. Effect of anti-
apoptotic antioxidants and calcium. J Biol Chem 2001;276:47266- 
76.
  15.   Wu S, Ko YS, Teng MS, Ko YL, Hsu LA, Hsueh C, et al. Adriamycin-
induced cardiomyocyte and endothelial cell apoptosis: in vitro and 
in vivo studies. J Mol Cell Cardiol 2002;34:1595-607.
  16.   Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, 
Delagrange D, et al. Close relation of endothelial function in the 
human coronary and peripheral circulations. J Am Coll Cardiol 
1995;26:1235-41.
  17.   Oudin C, Simeoni MC, Sirvent N, Contet A, Begu-Le Coroller A, 
Bordigoni P, et al. Prevalence and risk factors of the metabolic 
syn  drome in adult survivors of childhood leukemia. Blood 2011; 
117:4442-8.